This article was originally published in The Gray Sheet
Executive SummaryIn vitro diagnostics firms terminate their Dec. 22 merger agreement. "In response to disappointing test results and its loss of collaborative partner support," Cortech "has substantially reduced its staffing and has effectively discontinued all internal research and development activities" and is "currently evaluating its strategic alternatives," Cortech states. Valued at about $18.7 mil., the acquisition of BioStar would have shifted Cortech's focus toward point-of-care diagnostics ("The Gray Sheet" Jan. 5, I&W-3)
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.